Lu Cenbin, Kirsch Benjamin, Maurer Christine K, de Jong Johannes C, Braunshausen Andrea, Steinbach Anke, Hartmann Rolf W
Helmholtz-Institute for Pharmaceutical Research Saarland, Campus C2.3, 66123 Saarbrücken, Germany.
Helmholtz-Institute for Pharmaceutical Research Saarland, Campus C2.3, 66123 Saarbrücken, Germany; Pharmaceutical and Medicinal Chemistry, Saarland University, Campus C2.3, 66123 Saarbrücken, Germany.
Eur J Med Chem. 2014 May 22;79:173-83. doi: 10.1016/j.ejmech.2014.04.016. Epub 2014 Apr 5.
Increasing antibiotic resistance urgently requires novel therapeutic options to combat bacterial infections. The anti-virulence therapy selectively intervening with pathogenicity without affecting bacterial viability is such a strategy to overcome resistance. We consider the virulence regulator PqsR as an attractive target in the human pathogen Pseudomonas aeruginosa, and recently discovered the first PqsR antagonists, which, however, suffered from poor aqueous solubility. In this work, the antagonists were structurally modified to become more soluble, and their structure-activity as well as structure-property relationships were studied. A novel promising compound with improved solubility and enhanced anti-virulence activity was discovered (IC50: 3.8 μM, pyocyanin). Our findings emphasize the crucial role of substituents at the 3-position and the carbonyl group at the 4-position for ligand-receptor interactions, and illuminate the way for further optimization of PqsR antagonists as anti-virulence agents.
抗生素耐药性不断增加,迫切需要新的治疗方法来对抗细菌感染。抗毒力疗法通过选择性干预致病性而不影响细菌活力,是一种克服耐药性的策略。我们认为毒力调节因子PqsR是人类病原体铜绿假单胞菌中一个有吸引力的靶点,并且最近发现了首个PqsR拮抗剂,然而,这些拮抗剂的水溶性较差。在这项工作中,对拮抗剂进行了结构修饰以提高其溶解度,并研究了它们的构效关系以及结构-性质关系。发现了一种具有改善溶解度和增强抗毒力活性的新型有前景的化合物(IC50:3.8 μM,绿脓菌素)。我们的研究结果强调了3位取代基和4位羰基在配体-受体相互作用中的关键作用,并为进一步优化PqsR拮抗剂作为抗毒力药物指明了方向。